Quantum Genomics, a biotechnology company specializing in cardiovascular and metabolic diseases, has announced the termination of exclusive negotiations with Vistacare Medical for a potential merger. Following extensive audits, Quantum Genomics has determined that the financial prospects and challenges associated with Vistacare Medical’s ownership structure are not conducive to the envisioned transaction while protecting the interests of its shareholders.

Instead, Quantum Genomics is now turning its attention to privately held HealthTech companies that meet its selection criteria. These criteria include a significant presence in the healthcare sector, an innovative and distinctive project, an ability to replicate expertise on an international scale, and a high-performing team that complements Quantum Genomics’ strengths.

The objective for Quantum Genomics is to pursue a business project that leverages its existing assets, which include cash reserves of 4.5 million euros, including 2.5 million euros in Research Tax Credit, its stock market listing, and the expertise of its management team. By resuming discussions with other HealthTech companies, Quantum Genomics aims to identify a partner that aligns with its strategic goals and can contribute to its growth and success.

Quantum Genomics will release its financial results for the first half of 2023 on October 24, 2023. This update will provide stakeholders with insights into the company’s ongoing performance and financial health.

For more information about Quantum Genomics, please visit their website at www.quantum-genomics.com. Stay updated on their latest news and developments by following them on Twitter and LinkedIn.

Frequently Asked Questions

1. What is Quantum Genomics?

Quantum Genomics is a biotechnology company that specializes in the research and development of innovative drugs to address cardiovascular and metabolic diseases.

2. Why did Quantum Genomics terminate exclusive negotiations with Vistacare Medical?

Following thorough audits, Quantum Genomics determined that the financial prospects and challenges associated with Vistacare Medical’s ownership structure were not conducive to the envisioned merger, while still protecting the interests of its shareholders.

3. What are the criteria for selecting HealthTech companies to resume discussions with?

Quantum Genomics is seeking HealthTech companies that have a significant presence in the healthcare sector, an innovative and distinctive project, an ability to replicate expertise on an international scale, and a high-performing team that complements Quantum Genomics.

4. What assets does Quantum Genomics possess?

Quantum Genomics has cash reserves amounting to 4.5 million euros, including 2.5 million euros in Research Tax Credit. The company also has a stock market listing and a management team with expertise in the field.

5. When will Quantum Genomics release its financial results for the first half of 2023?

Quantum Genomics will release its financial results for the first half of 2023 on October 24, 2023.